News

Zhengzhou University Henan Cancer Hospital (ZUHCH) and Proteomedix enter into a cooperation to clinically validate biomarker tests and bioinformatics for prostate cancer diagnostics

Beijing, CN, Henan, CN and Zurich-Schlieren, CH, January 14, 2021. Henan Cancer Hospital and Proteomedix, the Swiss cancer diagnostics company announce today a strategic partnership to validate the Proclarix® prostate cancer diagnostics test in the local population and further develop comprehensive solutions for patient management in prostate cancer diagnostics. The leading...

read more

Results published of PROPOSe, a real-life prospective study of Proclarix, a novel blood-based test to support challenging biopsy decision making in prostate cancer

Zurich-Schlieren, Switzerland, January 07, 2021 - Proteomedix, the Swiss cancer diagnostics company, announced today that the results of PROPOSe, a prospective multicenter study of Proclarix® in clinical routine use, were published in European Urology Oncology1). Prostate specific antigen (PSA)-based detection of prostate cancer (PCa) often leads to negative biopsy results or...

read more

Collagen Matrix Acquires the GUIDOR® Synthetic Bone Graft & Membrane Business from Sunstar

OAKLAND, N.J., Dec. 29, 2020 /PRNewswire/ -- Collagen Matrix, Inc., a global leader in regenerative, collagen-based, xenograft-derived medical devices, and portfolio company of Linden Capital Partners ("Linden"), announced today the acquisition of Sunstar's Degradable Solutions division (the "Company"), including its GUIDOR® branded line of resorbable synthetic medical implants. Founded in 1999, Degradable Solutions AG, is...

read more

Molecular Partners Announces New Clinical Data, Immunomodulation Platform Advances, and Virology Portfolio Strategy

Zurich-Schlieren, Switzerland, December 17, 2020. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced multiple advances across clinical and preclinical programs, as well as an expansion of its corporate strategy to develop a portfolio...

read more

Swiss Center for Laboratory Medicine St. Gallen presents data from Proclarix® at American Association for Clinical Chemistry (AACC) Annual Scientific Meeting

Schlieren and St. Gallen, Switzerland, December 10, 2020 - The Center for Laboratory Medicine in St. Gallen and Proteomedix, the Swiss cancer diagnostics company, announced that Prof. Dr. med. Wolfang Korte who leads the Center for Laboratory Medicine will present new data from the implementation of Proclarix® in their laboratory...

read more